These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

617 related articles for article (PubMed ID: 28471106)

  • 21. BETTER PROGNOSIS FOR EYES WITH PRESERVED FOVEAL DEPRESSION AFTER INTRAVITREAL RANIBIZUMAB INJECTION FOR MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION.
    Kitagawa S; Yasuda S; Ito Y; Ueno S; Iwase T; Terasaki H
    Retina; 2018 Jul; 38(7):1354-1360. PubMed ID: 28538263
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-life clinical data for dexamethasone and ranibizumab in the treatment of branch or central retinal vein occlusion over a period of six months.
    Winterhalter S; Eckert A; Vom Brocke GA; Schneider A; Pohlmann D; Pilger D; Joussen AM; Rehak M; Grittner U
    Graefes Arch Clin Exp Ophthalmol; 2018 Feb; 256(2):267-279. PubMed ID: 29185099
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dexamethasone Intravitreal Implant Therapy for Retinal Vein Occlusion Macular Oedema and Conversion to Ranibizumab in Clinical Practice.
    Balal S; Than J; Tekriwal S; Lobo A
    Ophthalmologica; 2018; 239(1):36-44. PubMed ID: 28950262
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of immediate versus deferred intravitreal Bevacizumab in macular oedema due to branch retinal vein occlusion: a pilot study.
    Khan MA; Mallika V; Joshi D
    Int Ophthalmol; 2018 Jun; 38(3):943-949. PubMed ID: 28432581
    [TBL] [Abstract][Full Text] [Related]  

  • 25. "Off-label" use of intravitreal bevacizumab in non-ischemic macular edema secondary to retinal vein obstructions.
    Dascalu AM; Popa-Cherecheanu A; Popa-Cherecheanu M; Nica A; Serban D
    Rom J Ophthalmol; 2016; 60(2):90-95. PubMed ID: 29450329
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Short-term efficacy of intravitreal triamcinolone acetonide for macular edema secondary to retinal vein occlusion that is refractory to intravitreal bevacizumab.
    Yoo SG; Kim JH; Lee TG; Kim CG; Kim JW
    Indian J Ophthalmol; 2015 Jan; 63(1):25-9. PubMed ID: 25686058
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ranibizumab versus Dexamethasone Implant in Macular Edema Secondary to Branch Retinal Vein Occlusion: Two-year Outcomes.
    Ozkaya A; Tarakcioglu HN; Tanir I
    Optom Vis Sci; 2018 Dec; 95(12):1149-1154. PubMed ID: 30451802
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intravitreal ranibizumab for macular oedema secondary to retinal vein occlusion: a retrospective study of 34 eyes.
    Puche N; Glacet A; Mimoun G; Zourdani A; Coscas G; Soubrane G
    Acta Ophthalmol; 2012 Jun; 90(4):357-61. PubMed ID: 20602625
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of Intravitreal Ranibizumab, Aflibercept, and Dexamethasone Implant after Bevacizumab Failure in Macular Edema Secondary to Retinal Vascular Occlusions.
    Hanhart J; Rozenman Y
    Ophthalmologica; 2017; 238(1-2):110-118. PubMed ID: 28535531
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Bevacizumab and Ranibizumab for macular edema due to retinal vein occlusions].
    Niederhauser N; Valmaggia C
    Klin Monbl Augenheilkd; 2013 Apr; 230(4):405-8. PubMed ID: 23629792
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical, anatomical, and electrophysiological assessments of the central retina following intravitreal bevacizumab for macular edema secondary to retinal vein occlusion.
    Loukianou E; Brouzas D; Chatzistefanou K; Koutsandrea C
    Int Ophthalmol; 2016 Feb; 36(1):21-36. PubMed ID: 25820576
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sustained Benefits from Ranibizumab for Central Retinal Vein Occlusion with Macular Edema: 24-Month Results of the CRYSTAL Study.
    Larsen M; Waldstein SM; Priglinger S; Hykin P; Barnes E; Gekkieva M; Das Gupta A; Wenzel A; Monés J;
    Ophthalmol Retina; 2018 Feb; 2(2):134-142. PubMed ID: 31047340
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
    Ding X; Li J; Hu X; Yu S; Pan J; Tang S
    Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intravitreal Dexamethasone Implant versus Intravitreal Ranibizumab for the Treatment of Macular Edema Secondary to Retinal Vein Occlusion in a Chinese Population.
    Gu X; Yu X; Song S; Dai H
    Ophthalmic Res; 2017; 58(1):8-14. PubMed ID: 28334720
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of two individualized treatment regimens with ranibizumab for diabetic macular edema.
    Ebneter A; Waldmeier D; Zysset-Burri DC; Wolf S; Zinkernagel MS
    Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):549-555. PubMed ID: 27714513
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Natural Short-term Course of Recurrent Macular Edema Following Intravitreal Bevacizumab Therapy in Branch Retinal Vein Occlusion.
    Yoo SJ; Kim JH; Lee TG; Kim JW; Cho SW; Han JI
    Korean J Ophthalmol; 2017 Apr; 31(2):95-101. PubMed ID: 28367036
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination of Ranibizumab with macular laser for macular edema secondary to branch retinal vein occlusion: one-year results from a randomized controlled double-blind trial.
    Song S; Yu X; Zhang P; Gu X; Dai H
    BMC Ophthalmol; 2020 Jun; 20(1):241. PubMed ID: 32560639
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prospective comparisons of intravitreal injections of triamcinolone acetonide and bevacizumab for macular oedema due to branch retinal vein occlusion.
    Higashiyama T; Sawada O; Kakinoki M; Sawada T; Kawamura H; Ohji M
    Acta Ophthalmol; 2013 Jun; 91(4):318-24. PubMed ID: 22132711
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ranibizumab versus aflibercept for macular edema due to central retinal vein occlusion: 18-month results in real-life data.
    Chatziralli I; Theodossiadis G; Moschos MM; Mitropoulos P; Theodossiadis P
    Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1093-1100. PubMed ID: 28214955
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Macular vessel reduction as predictor for recurrence of macular oedema requiring repeat intravitreal ranibizumab injection in eyes with branch retinal vein occlusion.
    Hasegawa T; Takahashi Y; Maruko I; Kogure A; Iida T
    Br J Ophthalmol; 2019 Oct; 103(10):1367-1372. PubMed ID: 30514711
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.